Our team consists of enthusiastic professionals with diverse backgrounds in healthcare, technology and business development.
We are driven by a shared passion for making a meaningful impact on the lives of women around the world.
ScanEasy is excited to unveil OneSense® — a revolutionary homebased breast cancer screening device, marking a significant leap in early cancer detection.
The current screening paradigm falls short, often resulting in latestage detection and diminished treatment efficacy. The National Breast Cancer Foundation insists on the need for early detection of breast cancer and recommends breast self-examination at least once a month.
However, breast cancer's rapid progression demands more frequent monitoring.
1
A woman's lifetime risk of a breast cancer diagnosis is about one in eight, yet early detection can offer a 99% survival rate if the cancer is identified before metastasis.
2
Conventional mammography, reliant on X-ray technology, limits screenings to an annual basis due to radiation exposure.
OneSense® solution
OneSense® emerges as the solution to this pressing challenge.
It empowers individuals to conduct safe, painless, and efficient breast tissue screenings in the comfort of their homes, free from ionizing radiation.
Harnessing the power of advanced artificial intelligence and machine learning
OneSense® meticulously analyzes imaging data to pinpoint the earliest indicators of breast cancer
including atypical tissue densities, calcifications, and tumor formations.
Key benefits of OneSense®
Gentle on the Body
Zero adverse effects on the body.
99% Treatment Success
Detection capability for tumors as small as 3-4 mm, corresponding to the localized, non-metastatic stage where treatment success rates soar to 99%.
App for Swift Results
User-friendly operation, enabling self-examinations that are swift and straightforward. The results are displayed in a convenient and understandable form in a special application on a smartphone.
economic aspects
The economic and healthcare implications of early breast cancer diagnosis are profound.
It can be roughly assumed that globally such savings would amount to at least $40 billion.
+
Lives saved and treatment costs reduced significantly through early detection.
OneSenSe® is ready to transition from working prototypes to mass production, poised to meet the needs of a potential global market of Hundreds of million people.
$ 150 B
Estimated Market Size.
The expected retail price of the device is very affordable and comparable to that of a smartphone.
+
OneSense® presents a substantial opportunity based on market size and device affordability.
get our pitch deck
Become a part of the OneSense® success story today
Oops! Something went wrong while submitting the form.
In the future,
we intend to expand our product portfolio to include effective pharmaceuticals, parapharmaceuticals and medical devices for cancer prevention and subsequent treatment. Our commitment to innovation and excellence drives us to continually seek new ways to improve the lives of people around the world.
